From Bench to Bedside: Review of Gene and Cell-Based Therapies and the Slow Advancement into Phase 3 Clinical Trials, with a Focus on Aastrom's Ixmyelocel-T

Stem Cell Reviews and Reports

Volumn 9, Issue 3, 2013, Pages 373-383

  Bartel, Ronnda L ^a   Booth, Erin ^a   Cramer, Caryn ^a   Ledford, Kelly ^a   Watling, Sharon ^a   Zeigler, Frank ^a  

^a NONE

Author keywords

Bone marrow; Cellular therapy; CLI; Critical limb ischemia; Gene therapy; Ixmyelocel T; Limb threatening ischemia; Mesenchymal stromal cell; PAD; Severe peripheral arterial disease; Stem cell

Indexed keywords

ANGIOGENESIS; BIOLOGICAL THERAPY; GENE THERAPY; HUMAN; LIMB; METHODOLOGY; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

CELL- AND TISSUE-BASED THERAPY; EXTREMITIES; GENETIC THERAPY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84878981581     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-013-9431-x     Document Type: Review

References (104)

1. FDA website accessed 03 October 2012: http://www. fda. gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/default. htm.
2. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine, 285, 1182-1186.
3. Dvorak, H., Orenstein, N., Carvallo, A., et al. (1979). Induction of a fibrin-gel investment: an early event in line 10 heptocarcinoma growth mediated by tumor-secreted products. Journal of Immunology, 122, 166-174.
4. Evans, M. J., & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature, 292, 154-156.
5. Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the National Academy of Sciences, 78, 7634-7638.
6. Brunt, K., Weisel, R., & Li, R.-K. (2012). Stem cells and regenerative medicine-future perspectives. Canadian Journal of Physiology and Pharmacology, 90, 327-335.
7. Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., Fowkes, F. G., et al. (2007). Inter-society consensus for the management of peripheral arterial disease (TASC II). European Journal of Vascular and Endovascular Surgery, 33(Suppl 1), S1-S75.
8. Varu, V., Hogg, M., & Kibbe, M. (2010). Critical limb ischemia. Journal of Vascular Surgery, 51, 230-241.
9. Pipinos, I., Judge, A., Selsby, J., et al. (2008). The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction. Vascular and Endovascular Surgery, 41, 481-489.
10. Pipinos, I., Judge, A., Selsby, J., et al. (2008). The myopathy of peripheral arterial occlusive disease: part 2. Oxidative stress, neuropathy, and shift in muscle fiber type. Vascular and Endovascular Surgery, 42(2), 101-112.
11. Nicoloff, A. D., Taylor, L. M., Jr., McLafferty, R. B., Moneta, G. L., & Porter, J. M. (1998). Patient recovery after infrainguinal bypass grafting for limb salvage. Journal of Vascular Surgery, 27, 256-263.
12. Treiman, G. S., Copland, S., Yellin, A. E., et al. (2001). Wound infections involving infrainguinal autogenous vein grafts: a current evaluation of factors determining successful graft preservation. Journal of Vascular Surgery, 33, 948-954.
13. Tretinyak, A. S., Lee, E. S., Kuskowski, M. M., Caldwell, M. P., & Santilli, S. M. (2001). Revascularization and quality of life for patients with limb-threatening ischemia. Annals of Vascular Surgery, 15(1), 84-88.
14. Sprengers, R. W., Teraa, M., Moll, F. L., de Wit, G. A., van der Graaf, Y., Verhaar, M. C., et al. (2010). Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. Journal of Vascular Surgery, 52(4), 843-849.
15. Nehler, M. R., Hiatt, W. R., & Taylor, L. M. (2003). Is revascularization and limb salvage always the best treatment for critical limb ischemia? Journal of Vascular Surgery, 37(3), 704-708.
16. http://seer. cancer. gov/statfacts/html/prost. html (accessed 08 October 2012).
17. http://seer. cancer. gov/statfacts/html/breast. html (accessed 08 October 2012).
18. Kaul, P., Armstrong, P. W., Chang, W. C., et al. (2004). Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. Circulation, 110, 1754-1760.
19. http://seer. cancer. gov/statfacts/html/colorect. html (accessed 08 October 2012).
20. Hartmann, A., Rundek, T., Mast, H., et al. (2001). Mortality and causes of death after first ischemic stroke: the Northern Manhattan stroke study. Neurology, 57(11), 2000-2005.
21. Isner, J. M., Walsh, K., Symes, J., et al. (1995). Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation, 91(11), 2687-2692.
22. Isner, J. M., Pieczek, A., Schainfeld, R., et al. (1996). Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet, 348(9024), 370-374.
23. Ouma, G., Jonas, R., Haris, M., & Mohler, E. (2012). Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vascular Medicine, 17, 174-192.
24. Ferrara, N. (2005). VEGF as a therapeutic target in cancer. Oncology, 69(Suppl 3), 11-16.
25. Hudlicka, O., Milkiewicz, M., Cotter, M. A., & Brown, M. D. (2002). Hypoxia and expression of VEGF-A protein in relation to capillary growth in electrically stimulated rat and rabbit skeletal muscles. Experimental Physiology, 87, 373-381.
26. Shah, P. B., & Losordo, D. W. (2005). Non-viral vectors for gene therapy: clinical trials in cardiovascular disease. Advances in Genetics, 54, 339-361.
27. Shibuya, M., & Claesson-Welsh, L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research, 312, 549-560.
28. van Wijngaarden, P., Coster, D. J., & Williams, K. A. (2005). Inhibitors of ocular neovascularization: promises and potential problems. JAMA: The Journal of the American Medical Association, 293, 1509-1513.
29. Ferrara, N., & Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-974.
30. Hughes, G. C., & Annex, B. H. (2005). Angiogenic therapy for coronary artery and peripheral arterial disease. Expert Review of Cardiovascular Therapy, 3, 521-535.
31. Simons, M. (2005). Angiogenesis: where do we stand now? Circulation, 111, 1556-6.
32. Mäkinen, K., Manninen, H., Hedman, M., et al. (2002). Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Molecular Therapy, 6, 127-133.
33. Rajagopalan, S., Mohler, E. R., 3rd, Lederman, R. J., et al. (2003). Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation, 108, 1933-1938.
34. Mathieu-Costello, O., Hoppeler, H., & Weibel, E. R. (1989). Capillary tortuosity in skeletal muscles of mammals depends on muscle contraction. Journal of Applied Physiology, 66, 1436-1442.
35. Lloyd, P. G., Prior, B. M., Yang, H. T., & Terjung, R. I. (2003). Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. American Journal of Physiology-Heart and Circulatory Physiology, 284, H1668-H1678.
36. Nikol, S., Baumgartner, I., van Belle, E., et al. (2008). Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Molecular Therapy, 16, 972-978.
37. Belch, J., Hiatt, W., Baumgartner, I., et al. (2011). Effect of fibroblast growth factor NV1FGF on amputation and death: a randomized placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet, 377, 1929-1937.
38. Mac Gabhann, F., Ji, J. W., & Popel, A. S. (2007). Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Annals of Biomedical Engineering, 35, 982-994.
39. Mac Gabhann, F., Ji, J. W., & Popel, A. S. (2007). VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. Journal of Applied Physiology, 102, 722-734.
40. Morishita, R., Aoki, M., Yo, Y., & Ogihara, T. (2002). Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocrine Journal, 49, 273-274.
41. Morishita, R., Nakamura, S., Hayashi, S., et al. (1999). Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension, 33, 1379-1384.
42. Cowin, A. J., Kallincos, N., Hatzirodos, N., et al. (2001). Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats. Cell and Tissue Research, 306, 239-250.
43. Powell, R. J., Goodney, P., Mendelsohn, F. O., Moen, E. K., & Annex, B. H. (2010). HGF-0205 Trial Investigators. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. Journal of Vascular Surgery, 52(6), 1525-1530.
44. Powell, R. J., Simons, M., Mendelsohn, F. O., et al. (2008). Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation, 118(1), 58-65.
45. Powell, R. J. (2012). Update on clinical trials evaluating the effect of biologic therapy in patients with critical limb ischemia. Journal of Vascular Surgery, 56(1), 264-266.
46. Guillemin, K., & Krasnow, M. A. (1997). The hypoxic response: huffing and HIFing. Cell, 89, 9-12.
47. Wenger, R. H., & Gassmann, M. (1997). Oxygen(es) and the hypoxia-inducible factor-1. Biological Chemistry, 378, 609-616.
48. Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences, 92, 5510-5514.
49. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002). Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science, 295, 858-861.
50. Chang, E. I., Loh, S. A., Ceradini, D. J., et al. (2007). Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia. Circulation, 116, 2818-2829.
51. Rey, S., Lee, K., Wang, C. J., et al. (2009). Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proceedings of the National Academy of Sciences, 106, 20399-20404.
52. Huang, L. E., Arany, Z., Livingston, D. M., & Bunn, H. F. (1996). Activation of hypoxiainducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. Journal of Biological Chemistry, 271, 32253-32259.
53. Safran, M., & Kaelin, W. G., Jr. (2003). HIF hydroxylation and the mammalian oxygensensing pathway. The Journal of Clinical Investigation, 111, 779-783.
54. Pugh, C. W., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine, 9, 677-684.
55. Kaelin, W. G., Jr., & Ratcliffe, P. J. (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell, 30, 393-402.
56. Vincent, K. A., Shyu, K. G., Luo, Y., et al. (2000). Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF- 1alpha/VP16 hybrid transcription factor. Circulation, 102, 2255-2261.
57. Sarkar, K., Fox-Talbot, K., Steenbergen, C., Bosch-Marce, M., & Semenza, G. L. (2009). Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proceedings of the National Academy of Sciences, 106, 18769-18774.
58. Hiasa, K., Ishibashi, M., Ohtani, K., et al. (2004). Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation, 109(20), 2454-2461.
59. Segers, V. F., & Lee, R. T. (2010). Protein therapeutics for cardiac regeneration after myocardial infarction. Journal of Cardiovascular Translational Research, 3(5), 469-477.
60. Segers, V. F., Revin, V., Wu, W., et al. (2011). Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. Circulation, 123(12), 1306-1315.
61. Murohara, T., Ikeda, H., Duan, J., et al. (2000). Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. The Journal of Clinical Investigation, 105, 1527-1536.
62. Crosby, J. R., Kaminski, W. E., Schatteman, G., et al. (2000). Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circulation Research, 87, 728-730.
63. Asahara, T., Masuda, H., Takahashi, T., et al. (1999). Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulation Research, 85, 221-228.
64. Capla, J. M., Ceradini, D. J., Tepper, O. M., et al. (2006). Skin graft vascularization involves precisely regulated regression and replacement of endothelial cells through both angiogenesis and vasculogenesis. Plastic and Reconstructive Surgery, 117, 836-844.
65. Shi, Q., Rafii, S., Wu, M. H., et al. (1998). Evidence for circulating bone marrow-derived endothelial cells. Blood, 92, 362-367.
66. Takahashi, T., Kalka, C., Masuda, H., et al. (1999). Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Medicine, 5, 434-438.
67. Shintani, S., Murohara, T., Ikeda, H., et al. (2001). Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation, 103, 897-903.
68. Kalka, C., Masuda, H., Takahashi, T., et al. (2000). Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proceedings of the National Academy of Sciences, 97(7), 3422-3427.
69. Sprengers, R. W., Lips, D. J., Moll, F. L., & Verhaar, M. C. (2008). Progenitor cell therapy in patients with critical limb ischemia without surgical options. Annals of Surgery, 247, 411-420.
70. Lawall, H., Bramlage, P., & Amann, B. (2010). Stem cell and progenitor cell therapy in peripheral artery disease. Thrombosis and Haemostasis, 103, 696-709.
71. Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970). The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell and Tissue Kinetics, 3, 393-403.
72. Piersma, A. H., Brockbank, K. G., Ploemacher, R. E., van Vliet, E., Brakel-van Peer, K. M., & Visser, P. J. (1985). Characterization of fibroblastic stromal cells from murine bone marrow. Experimental Hematology, 13, 237-243.
73. Caplan, A. I. (1986). Molecular and cellular differentiation of muscle, cartilage, and bone in the developing limb. Progress in Clinical and Biological Research, 217B, 307-318.
74. Pittenger, M. F., Mackay, A. M., Beck, S. C., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
75. Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A. M., & Silberstein, L. E. (2006). Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells, 24, 1030-1041.
76. Ji, J. F., He, B. P., Dheen, S. T., & Tay, S. S. (2004). Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells, 22, 415-427.
77. Ponte, A. L., Marais, E., Gallay, N., et al. (2007). The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells, 25, 1737-1745.
78. Ringe, J., Strassburg, S., Neumann, K., et al. (2007). Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. Journal of Cellular Biochemistry, 101, 135-146.
79. Sordi, V., Malosio, M. L., Marchesi, F., et al. (2005). Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood, 106, 419-427.
80. Zvaifler, N. J., Marinova-Mutafchieva, L., Adams, G., et al. (2000). Mesenchymal precursor cells in the blood of normal individuals. Arthritis Research, 2(6), 477-488.
81. Erices, A., Conget, P., & Minguell, J. J. (2000). Mesenchymal progenitor cells in human umbilical cord blood. British Journal of Haematology, 109, 235-242.
82. Zuk, P. A., Zhu, M., Ashjian, P., et al. (2002). Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell, 13(12), 4279-4295.
83. De Bari, C., Dell'Accio, F., Tylzanowski, P., & Luyten, F. P. (2001). Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis and Rheumatism, 44, 1928-1942.
84. Barlow, S., Brooke, G., Chatterjee, K., et al. (2008). Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells and Development, 17(6), 1095-1107.
85. Baksh, D., Yao, R., & Tuan, R. S. (2007). Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells, 25, 1384-1392.
86. van Weel, V., van Tongeren, R. B., van Hinsbergh, V. W., van Bockel, J. H., & Quax, P. H. (2008). Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. Annals of Vascular Surgery, 22(4), 582-597.
87. Shireman, P. K. (2007). The chemokine system in arteriogenesis and hind limb ischemia. Journal of Vascular Surgery, 45(Suppl A), A48-A56.
88. Goltry, K, Hampson, B, Venturi, N, Bartel, R. (2009). Large-scale production of adult stem cells for clinical use. In: Lakshmipathy, U, Chesnut, J. D., Thyagarajan, B., (editors). Emerging technology platforms for stem cells. John Wiley & Sons, Inc. p 153-68.
89. Bartel, R. L., Cramer, C., Ledford, K., et al. (2012). The Aastrom experience. Stem Cell Research & Therapy, 3(4), 26.
90. Ledford, K. J., Murphy, E. N., Zeigler, F., Bartel, R. L. (2012). Evidence for the beneficial effects of ixmyelocel-T in the treatment of critical limb ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology. April.
91. Powell, R. J., Marston, W. A., Berceli, S. A., et al. (2012). Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Molecular Therapy, 20(6), 1280-1286.
92. http://circ. ahajournals. org/cgi/content/meeting_abstract/124/21_MeetingAbstracts/A8547?sid= ba1839f3-67aa-4e92-838e-e72a7da27a92 (accessed 08 October 2012).
93. CLI Performance Goals Work Group web site. Available from: http://www. criticallimb. org/ (accessed 08 October 2012).
94. Ruponen, M., Hyvonen, Z., Urtti, A., & Yia-Hertuala, S. (2005). Nonviral gene delivery methods in cardiovascular diseases. Methods in Molecular Medicine, 108, 315-328.
95. Pernow, B., & Zetterquist, S. (1968). Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. Scandinavian Journal of Clinical & Laboratory Investigation, 21(3), 277-287.
96. ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [08 October 2012]. Available from: http://clinicaltrials. gov/ct2/results?term=critical+limb+ischemia&recr=Open&no_unk=Y&rslt=&type=&cond=&intr=stem+cells&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=2&rcv_s=&rcv_e=&lup_s=&lup_e=.
97. Benoit, E., O'Donnell, T. F. Jr., Iafrati, M. D., et al. (2011). The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. Journal of Translational Medicine, 9, 165.
98. Kusumanto, Y. H., van Weel, V., Mulder, N. H., et al. (2006). Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Human Gene Therapy, 17(6), 683-691.
99. Creager, M. A., Olin, J. W., Belch, J. J., et al. (2011). Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation, 124(16), 1765-1773.
100. Sprengers, R. W., Moll, F. L., Teraa, M., Verhaar, M. C., JUVENTAS Study Group. (2010). Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. Journal of Vascular Surgery, 51(6), 1564-1568.
101. Tateishi-Yuyama, E., Matsubara, H., Murohara, T., et al. (2002). Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet, 360(9331), 427-435.
102. Walter, D. H., Krankenberg, H., Balzer, J. O., et al. (2011). Intra-arterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circulation: Cardiovascular Intervention, 4(1), 26-37.
103. Losordo, D. (2010). Randomized double-blind, placebo controlled trial of autologous cd34+ cell therapy for critical limb ischemia: 1 year results. Circulation, 122, A16920.
104. Murphy, M. P., Lawson, J. H., Rapp, B. M., et al. (2011). Autologous bone marrow mononuclear cell therapy is safe and promotes amputation free survival in patients with critical limb ischemia. Journal of Vascular Surgery, 53(6), 1565-1574.